Neurotransmitter-Related Molecular Modeling Studies

This book focuses of the neurotransmission phenomenon. By definition, neurotransmitters are chemicals that enable communication, i.e., the flow of nerve impulses between nerve cells or between nerve cells and muscles and glands. Recently, one can distinguish excitatory and inhibitory mediators, both...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2022
Language:English
Physical Description:1 electronic resource (188 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993545069504498
ctrlnum (CKB)5690000000011949
(oapen)https://directory.doabooks.org/handle/20.500.12854/87533
(EXLCZ)995690000000011949
collection bib_alma
record_format marc
spelling Nowaczyk, Alicja edt
Neurotransmitter-Related Molecular Modeling Studies
Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
1 electronic resource (188 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
This book focuses of the neurotransmission phenomenon. By definition, neurotransmitters are chemicals that enable communication, i.e., the flow of nerve impulses between nerve cells or between nerve cells and muscles and glands. Recently, one can distinguish excitatory and inhibitory mediators, both of which are endo–exogenous compounds that control the function of the whole organism. From a chemical point of view, neurotransmitters belong to many different structural groups, such as amino acids (such as glycine), peptides (such as substance P, somatostatin), monoamines (such as noradrenaline or dopamine), purine derivatives (such as adenosine), gases (such as nitrogen, NO, carbon monoxide CO), and acetylcholine. From a medical point of view, disturbances in the concentration of neurotransmitters in the body result in the occurrence of mental disorders and diseases (such as depression, schizophrenia, Parkinson’s disease) and contribute to the occurrence of dementia (including Alzheimer’s disease), among other diseases. However, the problem is much wider. These disorders can lead to a number of cardiovascular diseases and can lead to the development of vascular diseases of the brain as well as in many other organs. Therefore, pharmacological intervention is a therapy that tries to interfere with regulatory processes year after year. Such treatments improve survival, reduce the frequency of readmission, and improve patients' quality of life.
English
Research & information: general bicssc
Chemistry bicssc
white matter hyperintensities
dysautonomia
genetic polymorphisms
dementia
levodopa
renin-angiotensin system
orthostatic hypotension
reserpine-induced fibromyalgia model
vortioxetine
ropinirole
serotonin and dopamine in fibromyalgia
mouse
dopamine
acetylcholine
glutamate
BDNF
serotonin
neurotransmitters
statins
neurodegenerative diseases
stroke
depression
androgenetic alopecia
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
mixed dyslipidemia
risk factors
halogenated pyrazolines
monoamine oxidase inhibitors
kinetics
reversibility
molecular dynamics
guanylate cyclase (GC)
chronic heart failure (CHF)
pulmonary arterial hypertension (PAH)
tiagabine
cardiac voltage-gated ion channels
molecular modeling
ECG study
SGLT2i
sodium-glucose cotransporter 2 inhibitors
neuroprotection
atheroprotection
mTOR
type 2 diabetes mellitus
cognitive impairment
inflammation
oxidative stress
antibiotics
neurotoxicity
adverse drug reaction
neurotransmission
5-HT receptors
gastrointestinal tract
3-0365-4277-9
3-0365-4278-7
Grześk, Grzegorz edt
Nowaczyk, Alicja oth
Grześk, Grzegorz oth
language English
format eBook
author2 Grześk, Grzegorz
Nowaczyk, Alicja
Grześk, Grzegorz
author_facet Grześk, Grzegorz
Nowaczyk, Alicja
Grześk, Grzegorz
author2_variant a n an
g g gg
author2_role HerausgeberIn
Sonstige
Sonstige
title Neurotransmitter-Related Molecular Modeling Studies
spellingShingle Neurotransmitter-Related Molecular Modeling Studies
title_full Neurotransmitter-Related Molecular Modeling Studies
title_fullStr Neurotransmitter-Related Molecular Modeling Studies
title_full_unstemmed Neurotransmitter-Related Molecular Modeling Studies
title_auth Neurotransmitter-Related Molecular Modeling Studies
title_new Neurotransmitter-Related Molecular Modeling Studies
title_sort neurotransmitter-related molecular modeling studies
publisher MDPI - Multidisciplinary Digital Publishing Institute
publishDate 2022
physical 1 electronic resource (188 p.)
isbn 3-0365-4277-9
3-0365-4278-7
illustrated Not Illustrated
work_keys_str_mv AT nowaczykalicja neurotransmitterrelatedmolecularmodelingstudies
AT grzeskgrzegorz neurotransmitterrelatedmolecularmodelingstudies
status_str n
ids_txt_mv (CKB)5690000000011949
(oapen)https://directory.doabooks.org/handle/20.500.12854/87533
(EXLCZ)995690000000011949
carrierType_str_mv cr
is_hierarchy_title Neurotransmitter-Related Molecular Modeling Studies
author2_original_writing_str_mv noLinkedField
noLinkedField
noLinkedField
_version_ 1796651448320131072
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04362nam-a2200961z--4500</leader><controlfield tag="001">993545069504498</controlfield><controlfield tag="005">20231214133523.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202207s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5690000000011949</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/87533</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995690000000011949</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Nowaczyk, Alicja</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Neurotransmitter-Related Molecular Modeling Studies</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (188 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This book focuses of the neurotransmission phenomenon. By definition, neurotransmitters are chemicals that enable communication, i.e., the flow of nerve impulses between nerve cells or between nerve cells and muscles and glands. Recently, one can distinguish excitatory and inhibitory mediators, both of which are endo–exogenous compounds that control the function of the whole organism. From a chemical point of view, neurotransmitters belong to many different structural groups, such as amino acids (such as glycine), peptides (such as substance P, somatostatin), monoamines (such as noradrenaline or dopamine), purine derivatives (such as adenosine), gases (such as nitrogen, NO, carbon monoxide CO), and acetylcholine. From a medical point of view, disturbances in the concentration of neurotransmitters in the body result in the occurrence of mental disorders and diseases (such as depression, schizophrenia, Parkinson’s disease) and contribute to the occurrence of dementia (including Alzheimer’s disease), among other diseases. However, the problem is much wider. These disorders can lead to a number of cardiovascular diseases and can lead to the development of vascular diseases of the brain as well as in many other organs. Therefore, pharmacological intervention is a therapy that tries to interfere with regulatory processes year after year. Such treatments improve survival, reduce the frequency of readmission, and improve patients' quality of life.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Research &amp; information: general</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemistry</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">white matter hyperintensities</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dysautonomia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genetic polymorphisms</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dementia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">levodopa</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">renin-angiotensin system</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">orthostatic hypotension</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">reserpine-induced fibromyalgia model</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">vortioxetine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ropinirole</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">serotonin and dopamine in fibromyalgia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mouse</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dopamine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">acetylcholine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glutamate</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BDNF</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">serotonin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neurotransmitters</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">statins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neurodegenerative diseases</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stroke</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">depression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">androgenetic alopecia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mixed dyslipidemia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">risk factors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">halogenated pyrazolines</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">monoamine oxidase inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">kinetics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">reversibility</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular dynamics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">guanylate cyclase (GC)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chronic heart failure (CHF)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pulmonary arterial hypertension (PAH)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tiagabine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cardiac voltage-gated ion channels</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular modeling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ECG study</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SGLT2i</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sodium-glucose cotransporter 2 inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neuroprotection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">atheroprotection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mTOR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">type 2 diabetes mellitus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cognitive impairment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oxidative stress</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibiotics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neurotoxicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adverse drug reaction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neurotransmission</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">5-HT receptors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gastrointestinal tract</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4277-9</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4278-7</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grześk, Grzegorz</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nowaczyk, Alicja</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grześk, Grzegorz</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:56:34 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-07-14 08:50:39 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5337823410004498&amp;Force_direct=true</subfield><subfield code="Z">5337823410004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337823410004498</subfield></datafield></record></collection>